As reactivation was simultaneously associated with increased BAFF levels, it can be speculated that the observed alterations correspond to an anti-PTLD signature, which could explain the lack of BAFF-associated B cell proliferation and consequently PTLD development in our study. The gene discussed is TNFSF13B; the disease is post-transplant lymphoproliferative disease.